Stock AnalizSI-BONE, Inc. SIBN
Medical/Dental Instruments · IPO 2018 · data as of November 13, 2026
SI-BONE, Inc. (SIBN) is a healthcare company listed in the US with a market value of about $1.1B. In the twelve months to September 30, 2026 it had revenue of $221M and net income of -$14M, a net margin of -6.2%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 22% a year, a 5-year average ROIC of -19%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 87% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $221M | $201M | $167M | $139M | $106M | $90M | $73M | $67M | $55M | $48M |
| Net income | -$14M | -$19M | -$31M | -$43M | -$61M | -$57M | -$44M | -$38M | -$17M | -$23M |
| Free cash flow | -$4M | -$9M | -$23M | -$27M | -$51M | -$46M | -$33M | -$34M | -$15M | -$18M |
| EPS (diluted) | $-0.31 | $-0.44 | $-0.75 | $-1.13 | $-1.79 | $-1.71 | $-1.50 | $-1.55 | $-2.20 | $-6.65 |
| Net margin | -6.2% | -9.4% | -18.5% | -31.2% | -57.6% | -62.7% | -59.5% | -57.1% | -31.5% | -48.0% |
| ROIC | — | -8.2% | -13.6% | -17.8% | -34.2% | -23.3% | -14.3% | -27.8% | -9.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $26.78, 14% above the current price; targets range from $23.00 to $32.00; the consensus rating is “Strong buy”; expected EPS is $-0.34 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is SI-BONE stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 87% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does SI-BONE pay a dividend?
Not currently.
Is SI-BONE a good stock to buy?
We do not give buy or sell advice. SI-BONE scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.